Recent studies on gastric cancer and ovarian cancer have also shown that CXCL9 could enhance or reverse resistance to immunotherapy related to the PD-1/PD-L1 axis (Zhao et al., 2020; Seitz et al., 2022). This evidence concerns the gene CXCL9 and gastric cancer.